2022
DOI: 10.20517/evcna.2022.20
|View full text |Cite
|
Sign up to set email alerts
|

Cell-free DNA as a biomarker in cancer

Abstract: Translational research of liquid biopsy is just at the edge of routine clinical application: an emerging validity of circulating tumor DNA (ctDNA) tests suggests its use for earlier cancer detection and better monitoring of minimal residual disease (MRD) and resistance development, thus offering earlier guidance for therapy choices with the intent to cure cancer. In this review, we focus on ctDNA as an advanced and standardized validated marker in liquid biopsy. We also discuss what will be needed to reach the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
17
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 13 publications
(17 citation statements)
references
References 79 publications
0
17
0
Order By: Relevance
“…Within the last 20 years, various methods were developed and applied which can be summarized with the term "liquid biopsy" (Figure 1) [39][40][41][42][43][44][45][46]. Basically, tumor cells or tumor derived nucleic acids, proteins, or EV can be detected in bodily fluids, which are repeatedly accessible and at a lower risk compared to tissue biopsy.…”
Section: Liquid Biopsymentioning
confidence: 99%
“…Within the last 20 years, various methods were developed and applied which can be summarized with the term "liquid biopsy" (Figure 1) [39][40][41][42][43][44][45][46]. Basically, tumor cells or tumor derived nucleic acids, proteins, or EV can be detected in bodily fluids, which are repeatedly accessible and at a lower risk compared to tissue biopsy.…”
Section: Liquid Biopsymentioning
confidence: 99%
“…A telomere-specific reverse transcriptase (hTERT) found in telomerase is similar in structure and function to viral transcriptase. The replicative capacity of CRCs and the risk of recurrence are increased by the overexpression of hTERT ( 45 ). hTERT appears to be a recurrent biomarker that may be utilized to track systemic treatment responses.…”
Section: Biomarkers For Early Detection Of Colorectal Cancermentioning
confidence: 99%
“…The replicative capacity of CRCs and the risk of recurrence are increased by the overexpression of hTERT(45). hTERT appears to be a recurrent biomarker that may be utilized to track systemic treatment responses.…”
mentioning
confidence: 99%
“…Liquid biopsy has become a milestone in modern medicine, which is extensively reviewed also by Eibl and Schneemann on major cancers and brain tumors [36][37][38]. A simplifying, schematic overview is shown in Figure 4.…”
Section: Liquid Biopsymentioning
confidence: 99%